Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accutane suicide hearing likely

Executive Summary

House Energy & Commerce/Oversight Subcommittee anticipates holding hearing on possible link between Roche's Accutane (isotretinoin) and suicide this spring. Roche has responded to parts of the committee's request for information related to the science behind the acne drug. Charles Bishop, the 15-year old who allegedly committed suicide by crashing an airplane into a Tampa skyscraper, was prescribed Accutane, Tampa police said. Toxicology reports that will determine if Bishop was taking the drug are expected to be complete in about two weeks...

You may also be interested in...



Roche Accutane House hearing

House Energy & Commerce/Oversight Subcommittee is understood to be planning a hearing on a possible link between Roche's Accutane (isotretinoin) and suicide for December. Committee had anticipated holding a hearing this past spring, but refocused its efforts on ImClone (1"The Pink Sheet" Jan. 14, p. 36)...

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.

COVID-19 Shows Remote Monitoring Can Work For Pre-Cert Program

In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel